Effect of Doxycycline in the Treatment of Macrolide Resistant Mycoplasma Pneumoniae Pneumonia in Children
Objective To investigate the effect of doxycycline in the treatment of macrolide resistant mycoplasma pneumoniae pneumonia(MPP)in children.Methods A total of 80 children with macrolide resistant MPP treated in the First Affiliated Hospital of Ningbo University from October 2022 to October 2023 were selected as the study ob-jects,and were divided into observation group(n=40)and control group(n=40)according to random number table method two groups.Both groups were given basic intervention such as relieving cough and resolving phlegm,replenish-ing water and liquid.On this basis,the control group was treated with azithromycin for 7 days,and the observation group was treated with doxycycline for 7 days.The clinical therapeutic effect was observed and analyzed between the two groups.Results The clinical total effectiveness rate of the observation group was 95.00%higher than that of the control group(77.50%),and the difference was statistically significant(χ2=5.164,P<0.05).The time for symptomatic relief of the observation group was significantly shorter than that of the control group,and the difference was statisti-cally significant(P<0.05).The levels of serum inflammatory factor indexes,such as serum C-reactive protein,interleu-kin-6,interleukin-17,were lower than those before the treatment,and the observation group was lower than the con-trol group,and the differences were statistically significant(all P<0.05).The level of interleukin-10 was higher than that before treatment,and the observation group was higher than the control group,and the differences were statisti-cally significant(both P<0.05).There was no statistically significant difference in the total incidence of adverse reac-tions between the two groups(P>0.05).Conclusion For children with macrolide resistant MPP,doxycycline treatment has obvious effect,can promote the relief of symptoms in children,reduce the level of inflammatory factors,and has good safety.
万方数据
维普
